Shares of AIM ImmunoTech Inc. (NYSE:AIM) saw unusually-strong trading volume on Monday . Approximately 3,384,999 shares traded hands during trading, an increase of 1,284% from the previous session’s volume of 244,655 shares.The stock last traded at $0.46 and had previously closed at $0.40.
Separately, Maxim Group raised shares of AIM ImmunoTech from a “hold” rating to a “buy” rating in a research report on Thursday, October 10th.
The company’s 50-day moving average price is $0.49. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.01 and a quick ratio of 3.01.
About AIM ImmunoTech (NYSE:AIM)
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading: What are benefits of a growth and income fund?
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.